Market closedNon-fractional
AbbVie/ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
ABBV
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology
Headquarters
North Chicago, United States
Employees
50,000
Website
www.abbvie.com
AbbVie Metrics
BasicAdvanced
$322B
Market cap
60.93
P/E ratio
$2.99
EPS
-
Beta
$3.03
Dividend rate
1.66%
Dividend yield
Price and volume
Market cap
$322B
Dividend rate
$3.03
Financial strength
Total debt to equity
924.059
Interest coverage (TTM)
7.84%
Management effectiveness
Valuation
Price to earnings (TTM)
60.927
Price to revenue (TTM)
5.854
Price to book
40.17
Price to tangible book (TTM)
-3.67
Dividend yield (TTM)
1.66%
Growth
Revenue change (TTM)
-1.83%
Earnings per share change (TTM)
-38.52%
3-year revenue growth (CAGR)
0.78%
3-year earnings per share growth (CAGR)
-6.92%
3-year dividend per share growth (CAGR)
-15.82%
What the Analysts think about AbbVie
Analyst Ratings
Majority rating from 30 analysts.
AbbVie Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
-13.92%
Net income
$1.4B
66.55%
Profit margin
11.12%
93.73%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.91
$2.95
$2.79
$2.31
-
Expected
$2.81
$2.86
$2.77
$2.23
$3.05
Surprise
3.69%
3.25%
0.84%
3.76%
-
AbbVie News
AllArticlesVideos
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
Benzinga·5 hours ago
Stocks on the move: Bristol Myers, Abbive, and Tesla
CNBC Television·7 hours ago
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PRNewsWire·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
Aug
15
AbbVie
Dividend·Payment
$1.55
Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $322B as of July 26, 2024.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 60.93 as of July 26, 2024.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of July 26, 2024, the dividend rate is $3.03 and the yield is 1.66%. AbbVie has a payout ratio of 0% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for August 15, 2024.
What is the beta indicator for AbbVie?
AbbVie (ABBV) does not currently have a Beta indicator.
Buy or sell AbbVie stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.